Psychiatric treatment considerations with direct acting antivirals in hepatitis C

Sanjeev Sockalingam, Alice Tseng, Pierre Giguere, David Wong, Sanjeev Sockalingam, Alice Tseng, Pierre Giguere, David Wong

Abstract

Background: Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy. Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions (DDIs) between DAAs and psychiatric medications.

Methods: We conducted a Pubmed search using relevant search terms and hand searched reference lists of related review articles. In addition, we searched abstracts for major hepatology conferences and contacted respective pharmaceutical companies for additional studies.

Results: Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can potentially interact with a variety of psychotropic agents via cytochrome P450 and p-glycoprotein interactions. Triazolam, oral midazolam, St. John's Wort, carbamazepine and pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants, anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence are summarized.

Conclusions: Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high. Consideration of DDIs is paramount to improving medication adherence and mitigating adverse effects during HCV therapy.

References

    1. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1–16. doi: 10.1055/s-2000-9506.
    1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982. doi: 10.1056/NEJMoa020047.
    1. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–965. doi: 10.1016/S0140-6736(01)06102-5.
    1. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416. doi: 10.1056/NEJMoa1012912.
    1. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–1206. doi: 10.1056/NEJMoa1010494.
    1. El-Sarag HB, Kunik M, Richardson P, Rabaneck L. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology. 2002;123:476–482. doi: 10.1053/gast.2002.34750.
    1. Yovtcheva SP, Rifai MA, Moles JK, Linden BJV. Psychiatric comorbidity among hepatitis C-positive patients. Psychosomatics. 2001;42:411–415. doi: 10.1176/appi.psy.42.5.411.
    1. Horikawa N, Yamazaki T, Izumi N, Uchihara M. Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study. Gen Hosp Psych. 2003;25:34–38. doi: 10.1016/S0163-8343(02)00239-6.
    1. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics. 2010;51(5):401–408.
    1. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P. A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord. 2007;103:83–90. doi: 10.1016/j.jad.2007.01.007.
    1. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942–947. doi: 10.1038/sj.mp.4001119.
    1. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willnebring ML. Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psych. 2004;26:237–240. doi: 10.1016/j.genhosppsych.2004.01.003.
    1. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics. 2001;42(4):365–367. doi: 10.1176/appi.psy.42.4.365.
    1. Sockalingam S, Links PS, Abbey SE. Suicide risk in hepatitis C and during interferon-alpha therapy: a review and clinical update. J Viral Hepat. 2011;18(3):153–160. doi: 10.1111/j.1365-2893.2010.01393.x.
    1. Schaefer M, Hintzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R, Friebe A, Heinz A, Kluschke M. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. Hepatology. 2007;46:991–998. doi: 10.1002/hep.21791.
    1. Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Clin Gastroenterol. 2010;44(9):e210–217. doi: 10.1097/MCG.0b013e3181d88af5.
    1. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I. Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care. 2012;24(12):1504–1513. doi: 10.1080/09540121.2012.672718.
    1. Vertex Pharmaceuticals Inc. Incivek (telaprevir) Product Monograph. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2012.
    1. Merck Canada Inc. Victrelis (boceprevir) Product Monograph. Kirkland, QC: Merck Canada Inc; January 16, 2013.
    1. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol. 2012;84(8):1096–1102. doi: 10.1016/j.bcp.2012.07.032.
    1. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 2006;8(1):E101–111. doi: 10.1208/aapsj080112.
    1. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med. 2002;162(4):405–412. doi: 10.1001/archinte.162.4.405.
    1. Kipp G, Mohammad R, Lin A, Johnson H. The 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA; 2012. Evaluation of pharmacist identified and mitigated drug-drug interactions in hepatitis C virus infected patients starting telaprevir or boceprevir.
    1. Hulskotte EGJ, Feng H-P, Xuan F, van Zutven M, O’Mara E, Youngberg S, Wagner JA, Butterton JR. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Clin Infect Dis. 2013;56(5):718–726. doi: 10.1093/cid/cis968.
    1. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M, Bernasconi E, Calmy A. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15(3):413–423. doi: 10.3851/IMP1540.
    1. Sockalingam S, Abbey SE. Managing depression during hepatitis C treatment. Can J Psychiatry. 2009;54(9):614–625.
    1. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A, Forton D, Pariante CM. Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. J Hepatol. 2012;57(6):1379–1390. doi: 10.1016/j.jhep.2012.07.037.
    1. Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G, Schaffer A, Beaulieu S, McIntyre RS. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry. 2012;24(1):91–109.
    1. Baraldi S, Hepgul N, Mondelli V, Pariante CM. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32(4):531–543. doi: 10.1097/JCP.0b013e31825d9982.
    1. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen G, McIntyre RS, Sharma V, Ravindran A. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11(3):225–255. doi: 10.1111/j.1399-5618.2009.00672.x.
    1. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–1024. doi: 10.1056/NEJMoa1014463.
    1. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–2428. doi: 10.1056/NEJMoa1013086.
    1. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–716. doi: 10.1016/S0140-6736(10)60934-8.
    1. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–1217. doi: 10.1056/NEJMoa1009482.
    1. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Helnze L, Spengler U, Schlaepfer T, Relmer J, Bugglsch P. Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease. Ann Intern Med. 2012;157:94–103. doi: 10.7326/0003-4819-157-2-201207170-00006.
    1. Gleason OC, Fucci JC, Yates WR, Philipsen MA. Preventing relapse of major depression during interferon-alpha therapy for hepatitis C–A pilot study. Dig Dis Sci. 2007;52(10):2557–2563. doi: 10.1007/s10620-006-9729-5.
    1. Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, Wagner JA, Butterton JR. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Global Antiviral Journal. 2011;7(1):108–109. abstract.
    1. Van Heeswijk RPG, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V, Beaumont M. The pharmacokinetic interaction between escitalopram and the investigational HCV protease inhibitor telaprevir [abstract 12] Rev Antiviral Ther Infect Dis. 2010;5:12–13.
    1. Nichols AI, Behrle JA, Parks V, Richards LS, McGrory SB, Posener J, Patat A, Paul J. Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-norepinephrine reupatke inhibitor. J Bioequiv Availab. 2013;5:1.
    1. Zhou SF, Lai X. An update on clinical drug interactions with the herbal antidepressant St. John's wort. Current drug metabolism. 2008;9(5):394–409. doi: 10.2174/138920008784746391.
    1. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol. 2004;18(1):41–46. doi: 10.1177/0269881104040230.
    1. Dieperink E, Leskela J, Dieperink ME, Evans B, Thuras P, Ho SB. The effect of pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms. Psychosomatics. 2008;49(3):225–229. doi: 10.1176/appi.psy.49.3.225.
    1. Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG. Plasma levels of citalopram in depressed patients with hepatitis C. Psychosomatics. 2004;45(1):29–33. doi: 10.1176/appi.psy.45.1.29.
    1. Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry. 2002;63(3):194–198. doi: 10.4088/JCP.v63n0304.
    1. Gleason OC, Yates WR, Philipsen MA. Major depressive disorder in hepatitis C: an open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry. 2005;7(5):225–230. doi: 10.4088/PCC.v07n0503.
    1. Swinson RP, Antony MM, Bleau P, Chokka P, Craven M, Fallu A, Katzman M, Kjernisted K, Lanius R, Manassis K. Clinical Practice Guidelines: Management of Anxiety DIsorders. Can J Psychiatry. 2006;51(8):2.
    1. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. doi: 10.1136/bmj.f288.
    1. Lundbeck Canada Inc. Celexa (citalopram) Product Monograph. Montreal, QC: Lundbeck Canada Inc; 2012.
    1. Lundbeck Canada Inc. Cipralex (escitalopram) Product Monograph. Montreal, QC: Lundbeck Canada Inc; 2012.
    1. DeMaio W, Kane CP, Nichols AI, Jordan R. Metabolism studies of desvenlafaxine. J Bioequiv Availab. 2011;3:151–160.
    1. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci. 2000;54:565–572. doi: 10.1046/j.1440-1819.2000.00754.x.
    1. Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A, Parravicini P, Pioltelli P. Interferon-induced depression: prevalence and management. Dig Liver Dis. 2005;37(2):102–107. doi: 10.1016/j.dld.2004.09.018.
    1. Huet PM, Villeneuve JP. Determinants of drug disposition in patients with cirrhosis. Hepatology. 1983;3(6):913–918.
    1. Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E. 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA; 2011. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]
    1. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, Van Heeswijk RPG. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol. 2012;52(10):1566–1573. doi: 10.1177/0091270011419850.
    1. Luo X, Van Heeswijk RPG, Alves K, Garg V. The effect of telaprevir on the pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11] Rev Antiviral Ther Infect Dis. 2011;6:13.
    1. Rifai MA. Hepatitis C treatment of patients with bipolar disorder: a case series. Prim Care Companion J Clin Psychiatry. 2006;8(6):361–366. doi: 10.4088/PCC.v08n0607.
    1. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut. 1984;25(6):673–681. doi: 10.1136/gut.25.6.673.
    1. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid use for patients with hepatitis C infection. Am J Psychiatry. 2003;160(1):174–178. doi: 10.1176/appi.ajp.160.1.174.
    1. Argikar UA, Remmel RP. Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica; the fate of foreign compounds in biological systems. 2009;39(5):355–363. doi: 10.1080/00498250902745082.
    1. Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R, Yatham LN. The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry. 2012;24(1):6–22.
    1. Novartis Pharmaceuticals Canada Inc. Tegretol (Carbamazepine) Product Monograph. Dorval, Que: Novartis Pharmaceuticals Canada Inc; 2011.
    1. Andreasen AH, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia. 2007;48(3):490–496. doi: 10.1111/j.1528-1167.2007.00924.x.
    1. Hachad H, Ragueneau-Majlessi I, Levy RH. New antiepileptic drugs: review on drug interactions. Ther Drug Monit. 2002;24(1):91–103. doi: 10.1097/00007691-200202000-00016.
    1. Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC. Hepatitis C in schizophrenia: screening experience in a community-dwelling clozapine cohort. Psychosomatics. 2007;48(5):405–411. doi: 10.1176/appi.psy.48.5.405.
    1. Sockalingam S, Shammi C, Powell V, Barker L, Remington G. Determining rates of hepatitis C in a clozapine treated cohort. Schizophr Res. 2010;124(1–3):86–90.
    1. Matthews AM, Huckans MS, Blackwell AD, Hauser P. Hepatitis C testing and infection rates in bipolar patients with and without comorbid substance use disorders. Bipolar Disord. 2008;10(2):266–270. doi: 10.1111/j.1399-5618.2007.00472.x.
    1. Telio D, Sockalingam S, Stergiopoulos V. Persistent psychosis after treatment with interferon alfa: a case report. J Clin Psychopharmocol. 2006;26(4):446–447. doi: 10.1097/01.jcp.0000227348.59912.5d.
    1. Thome J, Knopf U. Acute psychosis after injection of pegylated interferon alpha-2a. Eur Psychiatry. 2003;18:142–143. doi: 10.1016/S0924-9338(03)00030-0.
    1. Garcia-Pares G, Domenech C, Gil M. Psychosis induced by interferon-alpha. Psychosomatics. 2002;43:428–429. doi: 10.1176/appi.psy.43.5.428.
    1. Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller M, Condermarin JR, Chiu NM, Jacobson JM. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV. Psychosomatics. 2003;44:417–420. doi: 10.1176/appi.psy.44.5.417.
    1. Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C. Addiction. 2000;95(7):1101–1104.
    1. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, Henry C. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66(8):1050–1057. doi: 10.4088/JCP.v66n0814.
    1. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry. 2004;161(3):429–435. doi: 10.1176/appi.ajp.161.3.429.
    1. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24(1):62–69. doi: 10.1097/01.jcp.0000104913.75206.62.
    1. Merck Canada Inc. MC. Saphris (asenapine) Product Monograph. Kirkland, QC: Merck Canada Inc; 2013.
    1. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol. 1997;44(5):439–446.
    1. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007;100(1):4–22. doi: 10.1111/j.1742-7843.2007.00017.x.
    1. English BA, Dortch M, Ereshefsky L, Jhee S. Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep. 2012;14(4):376–390. doi: 10.1007/s11920-012-0284-9.
    1. AstraZeneca Canada Inc. Seroquel (quetiapine) Product Monograph. Mississauga, ON: AstraZeneca Canada Inc; 2013. April 16.
    1. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS. Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2013;28(1):50–56. doi: 10.1097/YIC.0b013e32835ac9da.
    1. Liukkonen T, Sorjonen M, Jokelainen J, Timonen M. Treatment of hepatitis C with interferon-alpha and ribavirine in a patient with long-term clozapine treatment. Psychosomatics. 2008;49(1):86–88.
    1. Boulton DW, DeVane CL, Liston HL, Markowitz JS. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002;71(2):163–169. doi: 10.1016/S0024-3205(02)01680-6.
    1. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol. 2007;19(9):741–747. doi: 10.1097/MEG.0b013e3281bcb8d8.
    1. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms M, Raffa JD, DeVlaming S. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol. 2010;22(3):270–277. doi: 10.1097/MEG.0b013e32832a8c4c.
    1. Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V. Effect of telaprevir on the pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone maintenance therapy. Antimicrob Agents Chemother. 2012;56(7):3641–3647. doi: 10.1128/AAC.00077-12.
    1. Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE. A comparison of depression screening instruments in hepatitis C and the impact of depression on somatic symptoms. Psychosomatics. 2011;52(5):433–440.
    1. Hulskotte EGJ, Hwa-Ping F, Bruce RD, Webster LR, Xuan F, O'Mara E, Wagner JA, Butterton JR. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09] Cambridge, MA: 7th International Workshop on Clinical Pharmacology of Hepatitis Therapy; 2012. Rev Antiviral Ther Infect Dis 2012; 6:12.
    1. Dbouk B, Arguedas MR, Sheikh A. Assessment of the PHQ-9 as a screening tool for depression in patients with chronic hepatitis C. Dig Dis Sci. 2008;53:1100–1106. doi: 10.1007/s10620-007-9985-z.
    1. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR, Thuras P, Ho SB. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol. 2006;101(10):2254–2262. doi: 10.1111/j.1572-0241.2006.00731.x.
    1. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P. Antiviral therapy completion and response rates among hepatitis C patients with and without schizophrenia. Schizophr Bull. 2010;36(1):165–172. doi: 10.1093/schbul/sbn065.
    1. Sockalingam S, Blank D, Banga CA, Mason K, Dodd Z, Powis J. A novel program for treating patients with trimorbidity: hepatitis C, severe mental illness, and active substance use. Eur J Gastroenterol Hepatol. 2013. in press.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner